Stock Yards Bank & Trust Co. Sells 14,273 Shares of Pfizer Inc. (NYSE:PFE)

Stock Yards Bank & Trust Co. trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 10.5% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 122,188 shares of the biopharmaceutical company’s stock after selling 14,273 shares during the quarter. Stock Yards Bank & Trust Co.’s holdings in Pfizer were worth $3,419,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Cantor Fitzgerald Investment Advisors L.P. acquired a new position in Pfizer in the fourth quarter worth $16,166,000. LGT Group Foundation grew its holdings in Pfizer by 2.5% during the 2nd quarter. LGT Group Foundation now owns 742,875 shares of the biopharmaceutical company’s stock worth $20,786,000 after acquiring an additional 18,274 shares during the last quarter. ORG Partners LLC increased its position in Pfizer by 1,729.9% in the 2nd quarter. ORG Partners LLC now owns 47,028 shares of the biopharmaceutical company’s stock valued at $1,327,000 after acquiring an additional 44,458 shares in the last quarter. Kempner Capital Management Inc. bought a new position in shares of Pfizer in the first quarter worth about $2,439,000. Finally, Leo Wealth LLC acquired a new position in shares of Pfizer during the fourth quarter worth approximately $2,171,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 2.7 %

Shares of NYSE:PFE opened at $30.07 on Tuesday. The company has a 50 day moving average price of $29.26 and a two-hundred day moving average price of $28.15. The company has a market capitalization of $170.40 billion, a PE ratio of -501.08, a PEG ratio of 1.02 and a beta of 0.68. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $34.12. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping the consensus estimate of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. During the same quarter last year, the business posted $0.67 EPS. The firm’s revenue was up 2.1% compared to the same quarter last year. Analysts forecast that Pfizer Inc. will post 2.66 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 3rd. Investors of record on Friday, July 26th were given a $0.42 dividend. The ex-dividend date was Friday, July 26th. This represents a $1.68 annualized dividend and a dividend yield of 5.59%. Pfizer’s dividend payout ratio is presently -2,799.53%.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Wells Fargo & Company raised their price target on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. UBS Group boosted their target price on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research note on Monday. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and lifted their price objective for the stock from $28.00 to $34.00 in a research report on Wednesday, August 7th. Finally, Barclays upped their target price on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Eight research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $34.54.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.